Historical Context and Limitations
These medications entered clinical practice in the 1980s with the ambitious goal of replacing traditional cardiac glycosides. Pharmaceutical companies initially developed convenient oral formulations, including compounds such as ibopamine and milrinone.
However, clinical use revealed a serious drawback: at therapeutic doses, toxic manifestations occurred much more frequently and severely than with glycosides. The primary consequence of long-term use was an increase in overall patient mortality. For this reason, these medications are now used only temporarily, exclusively in emergency settings.
Classification of Non-Glycoside Cardiotonics
Modern pharmacology divides all drugs in this group into three major categories based on their primary molecular mechanism:
- Beta1-adrenergic receptor agonists — includes classic beta1-adrenomimetics (Dobutamine) and dopaminergic agents (Dopamine).
- Phosphodiesterase type III (PDE-III) inhibitors — represented by Milrinone.
- Calcium sensitizers — a unique group that includes Levosimendan.
Catecholamines and PDE Inhibitors
Dobutamine stimulates myocardial beta1-receptors via Gs-proteins and adenylate cyclase activation, leading to cAMP accumulation, opening of calcium channels, and a potent positive inotropic effect. The drug is administered via continuous intravenous infusion only; it acts rapidly (peak within 10 minutes) and has a half-life of just 2 minutes. Similarly, Dopamine is a norepinephrine precursor with marked dose-dependency: low doses dilate renal blood vessels, while high doses cause a pressor effect via alpha-adrenergic receptor stimulation.
Milrinone inhibits phosphodiesterase-III in cardiomyocytes and vascular smooth muscle. This leads to intracellular cAMP accumulation, increased myocardial contractility, and simultaneous direct vasodilation, which lowers systemic vascular resistance.
Characteristics of Calcium Sensitizers
The drug Levosimendan differs fundamentally from classic inotropes. Its molecular target is the N-terminal domain of troponin C. The drug increases the calcium sensitivity of contractile proteins without increasing intracellular calcium concentration.
Binding to troponin occurs selectively during systole, so ventricular diastolic relaxation is not impaired. Additionally, the drug activates ATP-sensitive potassium channels in vascular smooth muscle, causing pronounced vasodilation. Because it avoids intracellular calcium overload, levosimendan has a much lower arrhythmogenic potential compared to catecholamines.